Akouos (NASDAQ:AKUS) – FDA Clears Akouos’ Gene Therapy Trial For Genetic Form Of Hearing Loss
[ad_1] The FDA has signed off Akouos Inc’s AKUS Investigational New Drug application to initiate a Phase 1/2 trial of AK-OTOF, gene therapy for otoferlin gene (OTOF)-mediated hearing loss. OTOF-mediated hearing…
Atea Pharmaceuticals (NASDAQ:AVIR) – Atea Pharmaceuticals To Advance Global Late-Stage COVID-19 Study of Bemnifosbuvir
[ad_1] Atea Pharmaceuticals Inc AVIR announced additional details on its clinical development plans for bemnifosbuvir for COVID-19. Following meetings with the FDA and the European Medicines Agency Emergency Task Force, Atea…
Regeneron Pharmaceuticals (NASDAQ:REGN) – Regeneron’s Bispecific Antibodies Show Encouraging Anti Tumor Activity
[ad_1] Regeneron Pharmaceuticals Inc REGN announced early data for ubamatamab in recurrent ovarian cancer and REGN5093 in MET-altered advanced non-small cell lung cancer (NSCLC). Within 42 patients who received full doses…
Penumbra (NYSE:PEN) – Citing ‘Lightning Fast Growth,’ Needham Upgrades This Vascular Device Company
[ad_1] Needham upgraded Penumbra Inc PEN to Buy from Hold, with a price target of $244. The analyst notes that management indicated PEN is seeing stronger growth in 3Q22 due to…
Astrazeneca Plc (AZN), ASTRAZENECA PLC O (AZNCF) – AstraZeneca Imfinzi Combo Scores FDA Approval As First Immunotherapy Regimen For Biliary Tract Cancer
[ad_1] The FDA approved AstraZeneca plc’s AZN Imfinzi (durvalumab) for locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin). The approval was based on the…